2-methyl-1-(6-methyl-1H-benzo[d]imidazol-1-yl)-2-propanol | 1421683-56-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-methyl-1-(6-methyl-1H-benzo[d]imidazol-1-yl)-2-propanol
• 英文别名: 2-Methyl-1-(6-methylbenzimidazol-1-yl)propan-2-ol
• CAS: 1421683-56-8
• 化学式: C₁₂H₁₆N₂O
• 分子量: 204.272
• InChiKey: FMLYMJMXKQBPCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-1-(6-methyl-1H-benzo[d]imidazol-1-yl)-2-propanol 在 二叔丁基过氧化物 、 copper(l) chloride 作用下， 以 甲苯 为溶剂， 反应 8.0h， 以77%的产率得到2,2,6-trimethyl-2,3-dihydrobenzo[4,5]imidazo[2,1-b]oxazole
  参考文献：
  名称：

  Copper-Catalyzed C–H Alkoxylation of Azoles

  摘要：

  We achieved copper-catalyzed intramolecular and intermolecular alkoxylation of azoles. This reaction is a rare example of transition-metal-catalyzed C-H alkoxylation of heteroaromatic compounds. In addition, the alkoxylation reaction proceeded well even In gram scale. In most intermolecular alkoxylations, the use of an excess amount of alcohols (in some cases, alcohols are used as a solvent) is indispensable to efficiently promote the alkoxylation reaction, but this alkoxylation reaction proceeded using only 1 equiv of alcohols.

  DOI：

  10.1021/ol303533z
• 作为产物：
  描述：

  3-氟-4-硝基甲苯 在 palladium 10% on activated carbon 、 氢气 、 对甲苯磺酸 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 甲苯 、 乙腈 为溶剂， 反应 11.0h， 生成 2-methyl-1-(6-methyl-1H-benzo[d]imidazol-1-yl)-2-propanol
  参考文献：
  名称：

  Copper-Catalyzed C–H Alkoxylation of Azoles

  摘要：

  We achieved copper-catalyzed intramolecular and intermolecular alkoxylation of azoles. This reaction is a rare example of transition-metal-catalyzed C-H alkoxylation of heteroaromatic compounds. In addition, the alkoxylation reaction proceeded well even In gram scale. In most intermolecular alkoxylations, the use of an excess amount of alcohols (in some cases, alcohols are used as a solvent) is indispensable to efficiently promote the alkoxylation reaction, but this alkoxylation reaction proceeded using only 1 equiv of alcohols.

  DOI：

  10.1021/ol303533z

文献信息

• Non-basic melanin concentrating hormone receptor-1 antagonists
  申请人：Ahmad Saleem

  公开号：US20070093508A1

  公开（公告）日：2007-04-26

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了根据式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式。此外，本申请提供了含有至少一种根据式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱（例如肥胖症、糖尿病、抑郁症或焦虑症）的患者的方法，通过给予根据式I的化合物的治疗有效剂量。
• US7745447B2
  申请人：——

  公开号：US7745447B2

  公开（公告）日：2010-06-29
• [EN] THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS<br/>[FR] DERIVES DE THIENOPYRIMIDINONE UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR 1 DE L'HORMONE DE CONCENTRATION DE LA MELANINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2007050723A1

  公开（公告）日：2007-05-03

  [EN] The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula (I). Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula (I) and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula (I).
  [FR] L'invention concerne des composés, notamment tous les stéréoisomères, les solvates, les promédicaments et leurs formes pharmaceutiquement acceptables de formule (I). L'invention concerne, de plus, des compositions pharmaceutiques contenant au moins un composé de formule (I) et éventuellement un agent thérapeutique supplémentaire, ainsi que des méthodes pour traiter un patient souffrant de maladies ou de troubles médiés par la MCHR1, tels que l'obésité, le diabète, la dépression ou l'anxiété, comprenant l'administration d'une dose à efficacité thérapeutique d'un composé de formule (I).
• Copper-Catalyzed C–H Alkoxylation of Azoles
  作者：Noriaki Takemura、Yoichiro Kuninobu、Motomu Kanai

  DOI：10.1021/ol303533z

  日期：2013.2.15

  We achieved copper-catalyzed intramolecular and intermolecular alkoxylation of azoles. This reaction is a rare example of transition-metal-catalyzed C-H alkoxylation of heteroaromatic compounds. In addition, the alkoxylation reaction proceeded well even In gram scale. In most intermolecular alkoxylations, the use of an excess amount of alcohols (in some cases, alcohols are used as a solvent) is indispensable to efficiently promote the alkoxylation reaction, but this alkoxylation reaction proceeded using only 1 equiv of alcohols.